Trastuzumab plus capecitabine and docetaxel as first-line therapy for metastatic breast cancer: Phase II results

被引：0
|
作者：
Gennatas, C. G. [1 ]
Michalaki, V. [1 ]
Gennatas, S. [1 ]
机构：
[1] Univ Athens, Areteion Hosp, Athens, Greece
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1111
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Safety and efficacy of the combination of trastuzumab plus capecitabine and docetaxel as first-line therapy for metastatic breast cancer: phase II results
    Michalaki, V.
    Gennatas, S.
    Gennatas, C.
    [J]. EJC SUPPLEMENTS, 2009, 7 (02): : 276 - 276
  • [2] Trastuzumab plus Capecitabine and Docetaxel as First-line Therapy for HER2-positive Metastatic Breast Cancer: Phase II Results
    Michalaki, Vasiliki
    Fotiou, Stylianos
    Gennatas, Spyridon
    Gennatas, Constantine
    [J]. ANTICANCER RESEARCH, 2010, 30 (07) : 3051 - 3054
  • [3] Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results
    Michalaki, Vasiliki
    Gennatas, Spyridon
    Gennatas, Konstantine
    [J]. ANTI-CANCER DRUGS, 2009, 20 (03) : 204 - 207
  • [4] Randomized Phase II Trial of First-Line Trastuzumab Plus Docetaxel and Capecitabine Compared With Trastuzumab Plus Docetaxel in HER2-Positive Metastatic Breast Cancer
    Wardley, Andrew M.
    Pivot, Xavier
    Morales-Vasquez, Flavia
    Zetina, Luis M.
    Dias Gaui, Maria de Fatima
    Reyes, Douglas Otero
    Jassem, Jacek
    Barton, Claire
    Button, Peter
    Hersberger, Veronica
    Torres, Antonio Anton
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (06) : 976 - 983
  • [5] Trastuzumab plus docetaxel with or without capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer: a randomised Phase II study
    Wardley, A.
    Anton-Torres, A.
    Pivot, X.
    Morales-Vasquez, F.
    Zetina, L.
    Dias Gaui, M. da Fatima
    Reyes, D. Otero
    Jassem, J.
    Button, P.
    Bell, R.
    [J]. EJC SUPPLEMENTS, 2008, 6 (07): : 109 - 110
  • [6] Neoadjuvant capecitabine plus docetaxel ± trastuzumab therapy for recently diagnosed breast cancer:: phase II results
    Tripathy, D.
    Moisa, C.
    Gluck, S.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S226 - S226
  • [7] First-line chemotherapy with docetaxel plus capecitabine followed by capecitabine or hormone maintenance therapy for the treatment of metastatic breast cancer patients
    Liang, Xu
    Yan, Ying
    Wang, Lina
    Song, Guohong
    Di, Lijun
    Jiang, Hanfang
    Wang, Chaoying
    Li, Huiping
    [J]. ONCOLOGY LETTERS, 2015, 9 (02) : 987 - 993
  • [8] Trastuzumab as first-line therapy for metastatic breast cancer
    Lorenz, Judith
    [J]. GEBURTSHILFE UND FRAUENHEILKUNDE, 2023, 83 (07) : 776 - 776
  • [9] Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer
    Blum, Joanne L.
    Dees, E. Claire
    Chacko, Aparna
    Doane, Lisa
    Ethirajan, Sukumar
    Hopkins, Judith
    McMahon, Richard
    Merten, Suzan
    Negron, Angel
    Neubauer, Marcus
    Ilegbodu, Des
    Boehm, Kristi A.
    Asmar, Lina
    O'Shaughnessy, Joyce A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (27) : 4384 - 4390
  • [10] Superiority of Docetaxel plus Capecitabine Compared to Docetaxel plus Epirubicin as First-Line Therapy for Metastatic Breast Cancer - Final Results of the ERASME-4 Study.
    Bachelot, T.
    Bajard, A.
    Ray-Coquard, I
    Coeffic, D.
    Dramais, D.
    Ferri-Dessens, R.-M.
    Guastalla, J.-P.
    Perol, D.
    [J]. CANCER RESEARCH, 2009, 69 (24) : 625S - 625S
12345